Future For Spexis Looks Far From Secure
Swiss Biotech Launched End of 2021
Spexis is hoping to get ColiFin, a therapy for chronic lung infections in cystic fibrosis patients, onto the US market but cannot start the necessary late-stage program without an injection of cash.
You may also be interested in...
Polyphor In Peril After Breast Cancer Drug Failure
Polyphor has seen its remaining asset balixafortide bite the dust and "a strategic assessment regarding the future of the company" is underway for a firm that not so long ago was seen as a rising star in the Swiss biotech sector.
Road Ahead Unclear For Polyphor’s Intravenous Murepavadin
The Swiss firm is still examining options for the iv formulation of its novel antibiotic murepavadin even after it closed its two Phase III studies on safety concerns.
Sanofi Moves Up In MS With Frexalimab Success
Much of the focus on the French major’s MS pipeline has been on the BTK inhibitor tolebrutinib but promising Phase II data on frexalimab have caught the eye.